Patients are telling the truth — just not to you
September 21, 2026 | Data, Social Listening, clinical trials, patients
Patients are often most honest outside the clinic—revealing vital insights that can help clinical trial teams build trust, improve participation and collect better data.
There’s a familiar complaint in clinical research: patients don’t open up. They say they’re fine when they’re not. They under-report side effects. They nod through the consent conversation, and months later it’s clear they didn’t really follow it.
Spend an hour where patients talk to each other, though, and a different picture appears. They’re not guarded at all. They’re astonishingly honest — about what they fear, the side effects they hide, the days they can barely function. The truth isn’t missing. It’s just pointed somewhere other than the clinic.
That gap between what patients share with one another and what they tell the people providing their care is worth paying attention to. Because the things they don’t say out loud are usually the things a trial team most needs to hear.
What we miss in the room
It’s in patient communities where the quiet parts get said out loud.
On what it takes just to turn up, one person, deep into fertility treatment, wrote that they’d been going so long they had a favourite parking spot and no longer knew how to answer “how are you?” — “I am fine. I am functional.” The “fine” is doing a lot of work there.
On side effects, the honesty is sharper — and more uncomfortable. One cancer patient described hiding their symptoms “so I don’t have to wait another month for the next dose”.
Someone managing chronic pain put it plainly: they don’t tell the doctor about something that helps, “otherwise I’m an addict and not someone who needs help”. That isn’t non-compliance. It’s a calculation — that telling the truth might cost them their treatment.
Patients can also recognise when something isn’t right, sometimes before the clinical picture becomes clear. “The night of the procedure, I knew something was wrong,” one wrote — a concern later confirmed by the tests.
Some of this never gets said in the room. Some of it is said but not fully heard. All of it has value.
The silence isn’t soft — it shows up in your data
It’s tempting to file this under bedside manner. It isn’t. When patients don’t feel safe being honest, the consequences land exactly where a trial can least afford them.
Under-reported side effects create blind spots in safety data. The signals are there, they just aren’t always reaching you. Distress only becomes visible when someone quietly drops out. The burden of participation appears later as missed visits and withdrawals that seem to come from nowhere. A patient saying “I’m fine” isn’t a small social grace; it’s a missing data point. Honesty, in other words, isn’t a courtesy patients owe you. It’s the integrity of what you’re collecting.
Honesty is a design choice, not a personality trait
Patients aren’t withholding because they’re difficult or private. They’re withholding because, somewhere along the way, they learned that honesty has a cost — you lose the drug, you get dismissed, you become “the difficult one”, you worry people who already look worried.
So, the fix isn’t asking harder. It’s making honesty feel safer. That’s a design problem, and it runs through everything a participant touches: how a question is asked, how a reported side effect is met, whether the consent conversation invited questions or just collected a signature, whether the materials treat someone as an expert in their own condition or a beginner. Get those right and people tell you more, not because they suddenly trust strangers, but because the room made candour feel safer.
Start by listening where they’re already honest
If you want to understand what your participants aren’t saying, start where they’re already talking.
The version of the trial experience that rarely reaches the clinic already exists — in the open, in the communities where patients talk to one another. It will tell you which side effects people hide and why, what attending really costs, where the consent process loses them, and what they wish someone had asked. It’s the brief for every conversation you then design.
You don’t need to give people permission to speak openly in the abstract. Start by listening to what they’re already comfortable saying elsewhere. Then build the conditions where they’ll feel just as comfortable saying it to you.
Ready to talk?
Understanding what patients aren’t saying — and designing the materials and moments that help them say it — is what we do. If you want the real version of your participants’ experience, not just the version they feel able to share in clinic, let’s talk.
The patient voice here is drawn from public patient communities in our listening index, de-identified and lightly trimmed; medication names removed. It’s a self-selected, anonymous source — illustrative, not statistically representative — but it shows, in patients’ own words, the honest version they rarely say in clinic.
This content was provided by Cuttsy + Cuttsy
Company Details
Latest Content from Cuttsy + Cuttsy
UK clinical trial regs are changing — here’s what’s happening
Discover the transformative updates to UK clinical trial regulations, effective from April 2026, and learn how they aim to enhance transparency, participant safety, and trial efficiency.
The invisible influence on trial retention: why caregivers must be part of the plan
Caregivers are vital to clinical trial retention, yet often overlooked—this article highlights their challenges, impact, and how to better support them.
Where it all began: why we wrote ‘The Site Factor’
Discover the story behind ‘The Site Factor’ and how understanding site teams’ experiences can transform clinical trials for participants and researchers alike.
From text to context: Helping patients see side effects clearly
Discover how thoughtful design, clear language, and structured visuals can transform overwhelming side effect information into accessible, actionable insights for patients in our latest Health Literacy series.
Why patient engagement must come first in rare disease trials
Explore why patient engagement is the cornerstone of successful rare disease trials, emphasising the importance of designing studies around the realities of patients’ lives to build trust and improve outcomes.
New Cuttsy+Cuttsy research shows why site support matters more than ever
Cuttsy+Cuttsy’s upcoming report, ‘The site factor: Where protocol meets practice in clinical trials’, delves into the critical role of site staff in clinical research, offering insights into their daily challenges,…
Cuttsy+Cuttsy becomes employee owned
Cuttsy+Cuttsy announces its transition to employee ownership, celebrating 15 years of prioritising clients, patients, and its team while continuing under the leadership of founders Caroline Benson and Mathew Cutts.
Clinical research in 2026: The trends shaping tomorrow
Discover the key trends shaping clinical research in 2026, from patient-centric approaches to empowering site staff and fostering stronger human connections.
From overwhelming to actionable: Bringing lifestyle guidance to life
Discover how clear communication and health literacy principles can transform complex patient materials into simple, engaging, and empowering health information.
Behind the scenes: why we created ‘The participation equation’
Go behind the scenes of The participation equation – our call to put people, not just data, at the heart of clinical research.